Mapping global trends in vaccine sales before and during the first wave of the COVID-19 pandemic: a cross-sectional time-series analysis

Zeitouny, Seraphine; Suda, Katie J.; Mitsantisuk, Kannop; Law, Michael R.; Tadrous, Mina

doi:10.1136/bmjgh-2021-006874

Cited by 11 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data are internally validated each year through a standardized quality assurance program which validates sales data for each product against alternate sources by comparing estimated sales volumes against clients' actual sales volumes. 17 , 18 Medication sales data is projected to represent national pharmacy sales across all jurisdictions, regardless of payer. 17 Among the 66 countries in the current analysis, MIDAS captured an average of 89.5% of national sales.…”

Section: Methodsmentioning

confidence: 99%

International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID‐19 pandemic: A cross‐sectional analysis of 66 countries

Gomes

Kim

Suda

et al. 2022

Pharmacoepidemiology and Drug

Self Cite

View full text Add to dashboard Cite

Purpose We sought to compare trends in opioid purchasing between developed and developing economies to understand patterns of opioid consumption, and how they were impacted by the COVID‐19 pandemic. Methods We conducted a retrospective cross‐sectional study of retail pharmacy opioid sales from 66 jurisdictions between July 2014 and August 2020. We measured monthly population‐adjusted rate of opioid units purchased, stratified by development group and country, and used interventional time series analysis to assess the impact of the COVID‐19 pandemic on rates of opioid purchasing among developed and developing economies separately. Results Rates of opioid purchasing were generally higher among developed economies, although trends differed considerably by development group. Rates of opioid purchasing declined 23.8% (95% confidence interval [CI] −34.7% to 3.6%) in the 5 years prior to the pandemic in developed economies, but rose 15.2% (95% CI 4.6%–35.6%) among developing economies. In March 2020 there was a short‐term increase in the rate of opioid purchases in both developing (10.9 units/1000 population increase; p < 0.0001) and developed (145.5 units/1000 population; p < 0.0001) economies, which was followed immediately by reduced opioid purchasing of a similar scale in April–May 2020 (−14.8 and −171.8 units/1000 population in developing and developed economies, respectively; p < 0.0001). Conclusion The COVID‐19 pandemic led to disruptions in opioid purchasing around the world; although the specific impacts varied both between and among developed and developing economies. With global variation in opioid use, there is a need to monitor these trajectories to ensure the safety of opioid use, and adequate access to pain management globally.

show abstract

Section: Methodsmentioning

confidence: 99%

International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID‐19 pandemic: A cross‐sectional analysis of 66 countries

Gomes

Kim

Suda

et al. 2022

Pharmacoepidemiology and Drug

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many companies manufacturing the vaccine have benefited from the sales. An analysis carried out by Zeitouny et al revealed that the demand for vaccines was significantly higher in low and middle-income states compared to high-income states during the first wave of the pandemic ( 8 ). These factors imply that the enhanced demand for vaccines increased the need for more enterprises to manufacture the product.…”

Section: Discussionmentioning

confidence: 99%

The Development of Healthcare Jobs in the COVID-Pandemic—A New Economic Market

Bachmann

Enodien

Taha‐Mehlitz³

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThe COVID-19 pandemic commenced in China and has caused the death of numerous people globally. Despite the adverse effects, the outbreak has created room for job opportunities in healthcare, particularly the pharmaceutical domain. The main goal of this study is to examine how the current pandemic has triggered job creation in the healthcare domain and created a new economic market.MethodsThe study used the Preferred Reporting Items for Systematic and Meta-analyses for Scoping Review (PRISMA-ScR) to structure the manuscript and the subheadings to use. The source used to gather data is the PubMed database.ResultsThe study exclusively included fourteen articles, five of which focused on the pharmaceutical sector, three focused on vaccine sales, three on vaccination centers, and three on testing centers.ConclusionThe COVID-19 pandemic has created job opportunities in the healthcare sector. Most jobs are in the pharmaceutical sector, vaccination, and testing centers. However, more comprehensive research on the topic is necessary to gather conclusive outcomes on whether these jobs will be relevant after the pandemic.

show abstract

“…13–15 IQVIA-MIDAS covers 89.5% of all community-based and hospital-based pharmacy purchases of registered products. 16–18 Further database validation is included in online supplemental appendix B .…”

Section: Methodsmentioning

confidence: 99%

Effects of the July 2018 worldwide valsartan recall and shortage on global trends in antihypertensive medication use: a time-series analysis in 83 countries

et al. 2023

Self Cite

View full text Add to dashboard Cite

ObjectivesThis study aims to examine the effects of the July 2018 worldwide valsartan recall and shortage on global trends of antihypertensive medication use in 83 countries.MethodsA time-series analysis of monthly purchases of valsartan, other angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) across 83 countries from January 2017 to July 2020 was conducted using the IQVIA MIDAS database. Trends in outcomes were investigated globally and by economic level (developed vs developing economies). The valsartan recall’s impact on antihypertensive use was assessed with interventional autoregressive integrated moving average modelling.ResultsGlobal valsartan utilisation trends decreased significantly by 15.7% (−61 166 515 SU; p<0.0001), while global purchases of other ARBs increased by 44.8% (+958 069 420 SU; p=0.8523) and ACEIs increased by 1.6% (+44 106 747 SU; p=0.1102). Of the 32 developed countries, 20 (62.5%) showed a decline in 1-month percentage change in valsartan purchases, whereas only 10 out of 33 developing countries (30.3%) experienced a decrease in valsartan purchases. Mean 1-month, 3-month and 6-month percentage changes for developed countries were −1.2%, −9.3% and −12.2%, respectively, while the changes for developing countries were 25.0%, 7.3% and −1.2%.ConclusionsGlobal valsartan purchases substantially decreased post-recall, highlighting the far-reaching impacts of drug shortages. Opposing utilisation trends by economic level raise concerns of potential distribution of contaminated medications from developed countries to developing countries. Concerted actions for equitable global access to quality medications and mitigation of drug shortages are needed.

show abstract

Mapping global trends in vaccine sales before and during the first wave of the COVID-19 pandemic: a cross-sectional time-series analysis

Cited by 11 publications

References 22 publications

International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID‐19 pandemic: A cross‐sectional analysis of 66 countries

International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID‐19 pandemic: A cross‐sectional analysis of 66 countries

The Development of Healthcare Jobs in the COVID-Pandemic—A New Economic Market

Effects of the July 2018 worldwide valsartan recall and shortage on global trends in antihypertensive medication use: a time-series analysis in 83 countries

Contact Info

Product

Resources

About